AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Thorn GroupLtd

1.165

0.000

Volume:- -

Turnover:- -

Market Cap:40.50M

PE:3.99

High:1.165

Open:1.165

Low:1.165

Close:1.165

52wk High:1.165

52wk Low:1.165

Shares:34.76M

Float Shares:10.56M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.292

EPS(LYR):0.073

ROE:-5.00%

ROA:2.77%

PB:0.95

PE(LYR):15.85

Loading ...

Overview Company News Filings

Formosa Pharmaceuticals Partner Applied for Drug Review to Australian Drug Authority

MT Newswires Live

Fresh warning over unregulated ‘Barbie’ nasal spray that gives people fake tansSide effects from the drug include headaches, nausea, vomiting and facial redness, while reports associated with the peptide have included increased moles and freckles, kidney dysfunction and swelling of the brain.3 min read

Popular weight-loss drug users warned of rare but severe disorderThe regulator said no treatment has been shown to improve the condition once it develops.2 min read

4DMedical's Imaging Technology Secures TGA Approval

MT Newswires Live

Urgent recall for popular health supplements over glass riskThe products are sold nationwide at multiple chemists and some supermarkets.2 min read

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

NeuroScientific readies stem cell supply boost for bowel disease trials

The West Australian

Ceretone Launches in Australia with Flagship Core One Pro, Revolutionizing Access to Premium Hearing Solutions

Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

Optellum Secures TGA Approval to Expand AI-Enabled Lung Nodule Solution To Australia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/TGA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TGA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TGA.AU\",,,,,undefined,":{"symbol":"TGA.AU","market":"AU","secType":"STK","nameCN":"Thorn GroupLtd","latestPrice":1.165,"timestamp":1787551200000,"preClose":1.165,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Thorn GroupLtd","floatShares":10555948,"shares":34764019,"eps":0.291847,"marketStatus":"Closed","change":0,"latestTime":"08-24 16:00:00 AEST","open":1.165,"high":1.165,"low":1.165,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.291847,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":1.165,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TGA.AU\",,,,,undefined,":{"symbol":"TGA.AU","floatShares":10555948,"roa":"2.77%","roe":"-5.00%","lyrEps":0.073491,"shares":34764019,"dividePrice":0,"high":1.165,"amplitude":0,"preClose":1.165,"low":1.165,"week52Low":1.165,"pbRate":"0.95","psRate":"2.87","week52High":1.165,"institutionHeld":0,"latestPrice":1.165,"eps":0.291847,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.291847,"open":1.165,"prevYearClose":1.165,"prevWeekClose":1.165,"prevMonthClose":1.165,"prevQuarterClose":1.165,"fiveDayClose":1.165,"twentyDayClose":1.165,"sixtyDayClose":1.165},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TGA.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-12-13","symbol":"TGA.AU","reason":null,"defaultRemindTime":1702422000000,"announcedDate":"2023-12-11","type":"delisting","dateTimestamp":1702386000000},{"date":"2023-11-30","symbol":"TGA.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1701298800000,"name":null,"time":"","dateTimestamp":1701262800000,"actualEps":null},{"date":"2023-09-05","symbol":"TGA.AU","amount":0.45,"announcedDate":"2023-08-01","type":"dividend","market":"AU","newRecordDate":"2023-09-06","defaultRemindTime":1693872000000,"name":"Thorn GroupLtd","recordDate":"2023-09-22","payableDate":"2023-09-06","currency":"AUD","dateTimestamp":1693836000000,"payDate":"2023-09-22"},{"date":"2023-05-31","symbol":"TGA.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1685491200000,"name":null,"time":"","dateTimestamp":1685455200000,"actualEps":null},{"date":"2022-11-30","symbol":"TGA.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1669762800000,"name":null,"time":"","dateTimestamp":1669726800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TGA.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-10-16","recordDate":"2020-10-19","paymentDate":"2020-11-03","value":0.075,"currency":"AUD"},{"executeDate":"2021-07-02","recordDate":"2021-07-05","paymentDate":"2021-07-21","value":0.01,"currency":"AUD"},{"executeDate":"2022-01-24","recordDate":"2022-01-25","paymentDate":"2022-02-09","value":0.07,"currency":"AUD"},{"executeDate":"2022-07-06","recordDate":"2022-07-07","paymentDate":"2022-07-25","value":0.01,"currency":"AUD"},{"executeDate":"2022-08-24","recordDate":"2022-08-25","paymentDate":"2022-09-08","value":0.03,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TGA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661661228","title":"Formosa Pharmaceuticals Partner Applied for Drug Review to Australian Drug Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=2661661228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661661228?lang=en_us&edition=fundamental","pubTime":"2026-08-24 12:54","pubTimestamp":1787547279,"startTime":"0","endTime":"0","summary":"Formosa Pharmaceuticals  said its authorized partner, Arrotex Pharmaceuticals, has applied to the Therapeutic Goods Administration  of Australia for the drug inspection registration and review of the drug APP13007,  according to a Friday filing to the Taiwan stock exchange.The company's shares were down nearly 1% in Monday's trade.The drug is intended for the treatment of inflammation and pain after eye surgery.Arrotex Pharmaceuticals will bear all the costs associated with the application for drug inspection and registration.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QFN.AU","IISV.AU","TGA.AU","BEAR.AU","QRE.AU","IIGF.AU","E200.AU","VAP.AU","GEAR.AU","STW.AU","EIGA.AU","SLF.AU","IMLC.AU","BBOZ.AU","IOZ.AU","XJO.AU","BK7001","XKO.AU","OZR.AU","XAO.AU","VAS.AU","DACE.AU","ZYAU.AU","OZF.AU","GIVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660468281","title":"Fresh warning over unregulated ‘Barbie’ nasal spray that gives people fake tansSide effects from the drug include headaches, nausea, vomiting and facial redness, while reports associated with the peptide have included increased moles and freckles, kidney dysfunction and swelling of the brain.3 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2660468281","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660468281?lang=en_us&edition=fundamental","pubTime":"2026-08-18 00:00","pubTimestamp":1786982400,"startTime":"0","endTime":"0","summary":"Australia’s medicine regulator has issued a fresh warning over a nasal spray that gives people a fake tan after testing found wildly different doses in products carrying the same label.The warning com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/lifestyle/health-wellbeing/mt2-barbie-tan-peptide-warning-as-tga-seizes-nasal-spray-with-wildly-different-doses-c-22741245","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/lifestyle/health-wellbeing/mt2-barbie-tan-peptide-warning-as-tga-seizes-nasal-spray-with-wildly-different-doses-c-22741245","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["BK7001","TGA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653718926","title":"Popular weight-loss drug users warned of rare but severe disorderThe regulator said no treatment has been shown to improve the condition once it develops.2 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2653718926","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653718926?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:00","pubTimestamp":1784736000,"startTime":"0","endTime":"0","summary":"Australians taking popular weight-loss and diabetes medicines are being urged to watch for sudden vision loss after a new safety warning linked the drugs to a rare eye disorder.The Therapeutic Goods A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/news/new-warning-for-ozempic-wegovy-and-mounjaro-over-serious-eye-disorder-including-blindness-c-22616554","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/news/new-warning-for-ozempic-wegovy-and-mounjaro-over-serious-eye-disorder-including-blindness-c-22616554","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["BK4211","LU0106831901.USD","BK7001","BPOP","LU1668664300.SGD","TGA.AU","LU1791807156.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646672384","title":"4DMedical's Imaging Technology Secures TGA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2646672384","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646672384?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:11","pubTimestamp":1782429108,"startTime":"0","endTime":"0","summary":"4DMedical  secured Therapeutic Goods Administration  approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software CT:VQ, enabling commercial use across Australia, according to a Friday Australian bourse filing.The technology derives regional ventilation and perfusion information from standard non-contrast computed tomography  scans without the need for injections, contrast agents, or nuclear medicine infrastructure, per the filing.The company said CT:VQ is well positioned for scalable adoption across both urban and regional healthcare settings in Australia, where high CT scanner density could help improve access to functional lung imaging, the filing said.The company will now seek Medicare reimbursement through the Medical Services Advisory Committee, backed by clinical and health-economic evidence as well as real-world usage data, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IISV.AU","BK7094","BK7001","OZR.AU","VAS.AU","IMLC.AU","IOZ.AU","IIGF.AU","ZYAU.AU","DACE.AU","BEAR.AU","E200.AU","QFN.AU","SLF.AU","BBOZ.AU","4DX.AU","OZF.AU","GEAR.AU","XJO.AU","TGA.AU","XKO.AU","GIVE.AU","EIGA.AU","VAP.AU","XAO.AU","QRE.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640920338","title":"Urgent recall for popular health supplements over glass riskThe products are sold nationwide at multiple chemists and some supermarkets.2 min read","url":"https://stock-news.laohu8.com/highlight/detail?id=2640920338","media":"7NEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640920338?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:00","pubTimestamp":1780416000,"startTime":"0","endTime":"0","summary":"Two popular supplement products sold across Australia have been recalled over concerns glass fragments may be present inside some bottles.The Therapeutic Goods Administration  announced on Tuesday Sanofi Consumer Healthcare, the company behind the Nature’s Own vitamin and supplement range, is recalling specific batches of two products due to concerns some bottles may contain glass.The affected products are:. “There is a risk of users being cut when handling the product, and it could also be harmful if accidentally swallowed,” the regulator said.Consumers who have purchased either affected batch are being urged to stop using the product and return it to the place of purchase for a full refund.Customers seeking further information or wanting to arrange a refund can contact Sanofi Consumer Healthcare on 1800 451 453 or via recallchc@sanofi.com to return the affected product.Nature’s Own products are sold nationally through major pharmacies and health retailers, including Chemist Warehouse","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"7news_stock","url":"https://7news.com.au/news/natures-own-glucosamine-sulfate-with-chondroitin-and-magnesium-glycinate-recalled-over-glass-risk-c-22375887","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://7news.com.au/news/natures-own-glucosamine-sulfate-with-chondroitin-and-magnesium-glycinate-recalled-over-glass-risk-c-22375887","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"7news_stock","symbols":["TGA.AU","BK7001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633718922","title":"Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1","url":"https://stock-news.laohu8.com/highlight/detail?id=2633718922","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633718922?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:01","pubTimestamp":1778014860,"startTime":"0","endTime":"0","summary":"PEDMARQSI is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours. TGA registration provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy. AMSTERDAM, May 6, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company is pleased to announce that PEDMARQSI  has been registered by the Australian Therapeutic Goods Administration  for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours.Cisplatin is a widely used and important chemotherapeutic for children with solid tumours, but it carries a substantial risk of permanent hearing loss. Hearing loss in childhood can have profound and lifelong consequences, affecting speech and language development, education, social func","market":"other","thumbnail":"https://mma.prnewswire.com/media/2846726/5953601/Norgine_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2846726/5953601/Norgine_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/norgine-welcomes-tga-registration-in-australia-of-pedmarqsi-sodium-thiosulfate-anhydrous-for-the-prevention-of-cisplatin-induced-hearing-loss-in-children1-302762628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","PI","BK4533","BK4585","TGA.AU","BK4213","BK7001","CMI","TGA","PBS","LU0154245673.USD","LU0154245756.USD","XAO.AU","BK4149","LU0203347892.USD","LU0203345920.USD","XKO.AU","BK4567","LU1878469433.USD","XJO.AU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620415303","title":"NeuroScientific readies stem cell supply boost for bowel disease trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2620415303","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620415303?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:32","pubTimestamp":1773678737,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals has begun transferring production of its StemSmart stem cell therapy to Q-Gen in Brisbane, a key step towards phase two trials on Crohn’s disease and future commercial supply.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-21967996/7dd4315fab799b9df5c92dfa4edc893a2f2425ee.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-21967996/7dd4315fab799b9df5c92dfa4edc893a2f2425ee.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/public-companies/neuroscientific-readies-stem-cell-supply-boost-for-bowel-disease-trials-c-21967996","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/public-companies/neuroscientific-readies-stem-cell-supply-boost-for-bowel-disease-trials-c-21967996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK7001","TGA.AU","MSC","BK4213","TGA","BK4150","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617101577","title":"Ceretone Launches in Australia with Flagship Core One Pro, Revolutionizing Access to Premium Hearing Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2617101577","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617101577?lang=en_us&edition=fundamental","pubTime":"2026-03-06 08:00","pubTimestamp":1772755200,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, March 6, 2026 /PRNewswire/ --Ceretone, an innovative hearing technology brand, today announces its official entry into the Australian market. The company's comprehensive product line will launch on Chemist Warehouse's online platform in late February 2026, bringing affordable, high-performance hearing solutions to Australian consumers.Flagship Products Lead the Way. Hearing aids ready for use in Australia at Chemist Warehouse. Ceretone's Australian launch features two flagship models: Core One Pro and Beacon. Core One Pro stands out as one of the smallest rechargeable hearing aids available on the market, offering feather-light comfort and a remarkably discreet design. This virtually invisible profile empowers users to address their hearing needs confidently, without the social stigma often associated with traditional hearing aids.","market":"us","thumbnail":"https://mma.prnewswire.com/media/2924998/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2924998/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ceretone-launches-in-australia-with-flagship-core-one-pro-revolutionizing-access-to-premium-hearing-solutions-302704153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","TGA","XKO.AU","XAO.AU","XJO.AU","TGA.AU","BK7001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616516213","title":"Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2616516213","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616516213?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:33","pubTimestamp":1772465580,"startTime":"0","endTime":"0","summary":"Australia's Therapeutic Goods Administration , responsible for approval ofthe safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for registration via the provisional approval pathway.Skyhawk delivered its application for provisional approval to the TGA today.More than 115 patients are now on trial with SKY-0515.BOSTON, March 3, 2026 /PRNewswire/ --Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets for a series of challenging neurological diseases, announces that Australia's Therapeutic Goods Administration , responsible for the approval ofthe safety, quality, and efficacy of therapeutic goods, has determined that the Company's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligi","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2923501/Skyhawk_Therapeutics__Phase_1_Part_C_patient_cohort_cUHDRS.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2923501/Skyhawk_Therapeutics__Phase_1_Part_C_patient_cohort_cUHDRS.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/skyhawk-announces-australias-therapeutic-goods-administration-has-determined-sky-0515-for-huntingtons-disease-meets-eligibility-criteria-for-registration-via-the-provisional-approval-pathway-302701184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4083","SG9999001440.SGD","SKY","HD","LU0820561909.HKD","BK4566","XJO.AU","BK4588","LU1914381329.SGD","LU0354030438.USD","LU0868494617.USD","IE00B19Z4B17.USD","LU2461242641.AUD","LU1496350171.SGD","LU1093756168.USD","LU2361044865.SGD","XAO.AU","LU0823434583.USD","BK4533","IE00B66KJ199.SGD","BK4550","LU1989772840.SGD","XKO.AU","IE00BSNM7G36.USD","BK4585","LU1551013342.USD","LU0238689110.USD","LU0823434740.USD","IE00BKVL7J92.USD","LU0320765646.SGD","LU1989772923.USD","BK7001","BK4534","IE00B19Z6F94.USD","LU0868494708.USD","BK4213","BK4567","LU1778281490.HKD","BK4088","LU1929549753.HKD","TGA.AU","IE00B7SZL793.SGD","LU0234572021.USD","LU0823411888.USD","LU1674673691.USD","LU2361045086.USD","LU0943347566.SGD","TGA","IE0031619046.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614071800","title":"Optellum Secures TGA Approval to Expand AI-Enabled Lung Nodule Solution To Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071800","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071800?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139660,"startTime":"0","endTime":"0","summary":"OXFORD, England, Feb. 27, 2026 /PRNewswire/ -- Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration  class IIb approval in Australia for the Virtual Nodule Clinic  platform to support early lung cancer diagnosis. This important regulatory milestone was achieved after a rigorous review of technical documentation and validation studies, recognizing its safety and performance for clinical use. VNC helps identify, triage, and manage patients with pulmonary nodules, and includes a clinically validated AI decision support tool, lung cancer prediction  AI, already used in the US and EU/UK for nodule risk stratification.This TGA clearance poises Optellum to help thousands of patients in Australia by supporting earlier and more consistent identification of incidental lung nodules. By helping care teams prioritize higher-risk findings and streamline follow-up more efficiently, VNC aims to reduce","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2633244/Optellum_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2633244/Optellum_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/optellum-secures-tga-approval-to-expand-ai-enabled-lung-nodule-solution-to-australia-302698996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","BK4551","BK4588","BK7001","TGA.AU","BK4543","XKO.AU","XJO.AU","XAO.AU","BK4213","BK4587","AIYY","TGA","BK4023","BK4585"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}